Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.44 |
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913346 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL912858 | 0.90 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL29586206 | 0.90 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL912857 | 0.90 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL24771437 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL15494655 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL22927890 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL20516514 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL16217766 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1MAPT | |
| SCHEMBL404573 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4742901-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | claimed |
| EP-4742900-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | claimed |
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | claimed |
| EP-4651963-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | Inbiose N.V. (BE) | 2025-11-26 | — | — | EP | claimed |
| WO-2025012480-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | INBIOSE N.V. (BE) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012479-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | INBIOSE N.V. (BE) | 2025-01-16 | — | — | WO | claimed |
| WO-2024223815-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | INBIOSE N.V. (BE) | 2024-10-31 | — | — | WO | claimed |
| WO-2024153788-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2024-07-25 | — | — | WO | claimed |
| WO-2024039740-A2 | POLYPEPTIDE COMPOSITIONS CONTAINING NON-STANDARD GLYCAN STUB AMINO ACIDS AND METHODS OF MAKING AND USES THEREOF | GRO BIOSCIENCES INC. (US) | 2024-02-22 | — | — | WO | claimed |
| CN-116194149-A | Molecules with solubility tags and related methods | 默克专利股份公司 | 2023-05-30 | — | — | CN | claimed |
| US-20230029277-A1 | Abiotic Anti-VEGF Nanoparticle | MIURA YOSHIKO (JP) | 2023-01-26 | — | — | US | claimed |
| US-11458107-B2 | Abiotic anti-VEGF nanoparticle | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-04 | — | — | US | claimed |
| US-20060281708-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2006-12-14 | — | — | US | claimed |
| US-7098195-B2 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | HEALTH RESEARCH, INC. (US) | 2006-08-29 | — | — | US | claimed |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-07 | — | — | US | claimed |
| EP-4742900-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743567-A1 | CELLULAR PRODUCTION OF LACTO-N-TRIOSE (LN3)-CONTAINING OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-1461046-A2 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003093410-A2 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458107-B2 | Abiotic anti-VEGF nanoparticle | VEGFA, KDR, FLT1 | LMNA 3728/4885KMT2A 2201/4885POLB 1436/4885 |
| US-20230029277-A1 | Abiotic Anti-VEGF Nanoparticle | VEGFA, KDR, FLT1 | LMNA 3728/4885KMT2A 2201/4885POLB 1436/4885 |
| US-20060281708-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells | B3GAT3, UGGT1, FUT5 | LMNA 1769/4885KMT2A 3896/4885POLB 3985/4885 |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | FUT5, FUT6, OGT | LMNA 2371/4885KMT2A 3787/4885POLB 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.